{
    "ticker": "TRVI",
    "name": "Trevi Therapeutics, Inc.",
    "description": "Trevi Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients suffering from chronic cough and other conditions associated with chronic pain. Founded in 2016 and headquartered in New Haven, Connecticut, Trevi is dedicated to addressing unmet medical needs through the development of novel drug formulations. The company's lead product candidate, Haduvio (nalbuphine extended-release), is a treatment being evaluated for the management of chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other conditions. Trevi employs a patient-centric approach, leveraging extensive clinical research to ensure that its therapies not only improve patient outcomes but also enhance quality of life. The company aims to bring innovative solutions to the healthcare market, particularly for patients who suffer from debilitating chronic conditions that have limited treatment options. Trevi's commitment to advancing therapeutic development is underscored by its rigorous clinical trials and collaborative partnerships within the biopharmaceutical industry, striving to make a meaningful impact on patient care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New Haven, Connecticut, USA",
    "founded": "2016",
    "website": "https://www.trevitherapeutics.com",
    "ceo": "F. Andrew K. (Andy) Haffner",
    "social_media": {
        "twitter": "https://twitter.com/TreviThera",
        "linkedin": "https://www.linkedin.com/company/trevi-therapeutics/"
    },
    "investor_relations": "https://investors.trevitherapeutics.com",
    "key_executives": [
        {
            "name": "F. Andrew K. (Andy) Haffner",
            "position": "CEO"
        },
        {
            "name": "C. Keith M. H. K. D. (Keith) R. Blanchard",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Haduvio"
            ]
        }
    ],
    "seo": {
        "meta_title": "Trevi Therapeutics, Inc. | Innovative Therapies for Chronic Conditions",
        "meta_description": "Explore Trevi Therapeutics, Inc., focused on developing treatments for chronic cough and pain. Learn about their innovative product candidate Haduvio and commitment to patient care.",
        "keywords": [
            "Trevi Therapeutics",
            "Chronic Cough",
            "Biopharmaceuticals",
            "Haduvio",
            "Chronic Pain"
        ]
    },
    "faq": [
        {
            "question": "What is Trevi Therapeutics known for?",
            "answer": "Trevi Therapeutics is known for developing therapies for chronic cough and chronic pain, particularly its product candidate Haduvio."
        },
        {
            "question": "Who is the CEO of Trevi Therapeutics?",
            "answer": "The CEO of Trevi Therapeutics is F. Andrew K. (Andy) Haffner."
        },
        {
            "question": "Where is Trevi Therapeutics headquartered?",
            "answer": "Trevi Therapeutics is headquartered in New Haven, Connecticut, USA."
        },
        {
            "question": "What is Haduvio?",
            "answer": "Haduvio is an extended-release formulation of nalbuphine, being evaluated for chronic cough and other chronic pain conditions."
        },
        {
            "question": "When was Trevi Therapeutics founded?",
            "answer": "Trevi Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "VRTX",
        "PTCT",
        "SAGE",
        "ACAD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BIIB"
    ]
}